Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
You will find that purchase was prior to the share consolidation in 2019.
Very valid reason zebbo.
Spot on Si.
Now all the jealous haters will be out with their negativity.
Could this be great news for the Health Care sector and OO.
At this price there will be no flipping of placing shares.
Looks good for future revenue.
Placing done at not much of a discount. Looks very positive.
Courtesy of alphabravo321 on advfn;
Amryt is on Nasdaq website as AMRYY...
Good news FOR OO.
Good news of OO.
MIDAS SHARE TIPS: Amryt Pharma makes remedies that can save lives - and cheer savers By Joanne Hart for The Mail on Sunday PUBLISHED: 09:21 AEDT, 19 November 2017 | UPDATED: 09:21 AEDT, e- High cholesterol normally afflicts people in their 50s and above, often because they eat the wrong food and take too little exercise. In some cases, however, children are born with exceptionally high cholesterol, so much so that they are at risk from heart attacks and strokes before they even start school. The condition, known as HoFH, is rare, affecting about one in a million people, but those who are affected are not expected to survive into adulthood if they are left untreated. Even with treatment their life expectancy is about 45. The standard treatment for HoFH involves being strapped to a machine for hours every fortnight, much like dialysis. But there is an alternative � a simple capsule, called Lojuxta sold by Aim-listed Amryt Pharma. Lojuxta is licensed for adults and may be licensed for children. Helping hand: Amryt Pharma is developing a treatment for a rare condition that it hopes will be licensed for children Amryt is a drugs firm with a difference. It focuses on treatments for rare and �orphan� diseases, that is, conditions that affect fewer than one in 2,000 people. The shares are 17�p and deserve to be far higher. Amryt is chaired by Harry Stratford, who set up Shire in 1986, a drugs firm now valued at �33billion. Stratford also set up ProStrakan, a pharmaceutical firm sold to the Japanese for nearly �300million back in 2011. Amryt was founded four years later, in August 2015. Though a fairly new firm, it has crossed some important milestones. Many young biotech firms struggle as they focus on a single drug and take years to bring it to market. From the start Amryt spread its net wider. It does not spend time and money discovering new drugs. Instead, it acquires products that are either in trials or approved by regulators. The group then develops these products into fully-fledged medicines and sells them to those in need. +2 Today, there is a growing need for effective drugs to treat orphan diseases. The number of people affected may be small but there are about 7,000 such conditions and large pharmaceutical firms have historically paid scant attention to them. Thousands of conditions go untreated, sufferers are desperate for help and global orphan drug sales are expected to reach more than �150billion over the next five years. It is easier to gain regulatory approval for orphan drugs too, so treatments move from development to commercial sales much faster than conventional medicines. Amryt�s team is impressive. Not only is it chaired by a veteran of the industry, but chief executive Joe Wiley has spent 20 years in the healthcare and private equity sectors, having trained as a neurologist. The finance director, commercial officer, chief medical office
I particularly like the paragraph:"The Group has made substantial progress since its admission to trading on AIM in April 2016 and this has continued in the new financial year. "
Report card – an impressive first year Amryt Pharma is a specialty pharma company focused on acquiring, developing and commercialising drugs for the treatment of rare and orphan diseases. The company has had a frenetic first year as a public company. Having acquired two orphan drug development assets (Episalvan and AP102) in April 2016, the company went on to obtain European rights to Lojuxta to treat HoFH, a rare and fatal genetic disease, as well as securing a preferential €20 million EIB loan to fund future developments. With an encouraging start to Lojuxta sales, we recently added the product to our valuation of Amryt. Our 60p target price reflects the substantial upside opportunity we believe Amryt offers investors. Reiterate Buy. Phase III trial of Episalvan in epidermolysis bullosa (EB) pending. In March 2017, Amryt reached agreement with the FDA and EMA to a single pivotal trial design for a Phase III trial of Episalvan in EB. The blinded trial is expected to recruit 164 evaluable patients who will be treated for 90 days. The primary endpoint of the trial will be the proportion of patients with completely healed target wounds within 45 days. Secondary endpoints include time to wound healing and changes in pain and itch. An interim efficacy analysis, likely to occur in 1Q18, will be conducted after half the patients are recruited. Results from the trial are expected in 2H18. Thirty clinical sites in 15 countries have already been pre-qualified to participate in the study. We forecast sales of Episalvan in EB of $258 million by 2023 with launch in 2019. With around 55,000 sufferers in the US and Europe, EB represents a significant orphan drug condition with no current treatment other than regular bandaging. The genetic disorder is life threatening and represents an area of high unmet medical need. Lojuxta brings Amryt a commercial asset with growing sales. In December 2016, Amryt secured European commercial rights from Novelion Therapeutics Inc. to Lojuxta, an approved drug for the treatment of homozygous familial hypercholesterolaemia (HoFH), a rare and fatal genetic disease that results in extreme elevated cholesterol levels in the blood and formation of cholesterol deposits. In March 2017, Amryt announced Lojuxta sales achieved an annual run-rate of €10.5 million in its first three months. The company expects the product to be immediately self-funding. Reiterate Buy. We recently raised our target price reflecting our first time inclusion of Lojuxta in our valuation. Our target price is based on a hybrid of NPV, comparative and discounted revenue multiple methodologies. Our target price at 60p per share implies significant upside potential to the current share price.
having receive the 1 share buy signal.
and with NED from Frontier. New NED experience more relevant to Concepta.
Amryt Pharma (#AMYT) confirms launch of phase 3 clinical trial of AP101 . Looks good.
Amryt (AMYT)+ – Opportunity significantly de-risked; FV increased to 88p per share - House stock at 18.5p
Chinese Manufacturing Agreement Signed